Lung-Specific mRNA Delivery Enabled by Sulfonium Lipid Nanoparticles.
Nano Lett
; 24(26): 8080-8088, 2024 Jul 03.
Article
em En
| MEDLINE
| ID: mdl-38888232
ABSTRACT
Among various mRNA carrier systems, lipid nanoparticles (LNPs) stand out as the most clinically advanced. While current clinical trials of mRNA/LNP therapeutics mainly address liver diseases, the potential of mRNA therapy extends far beyondâyet to be unraveled. To fully unlock the promises of mRNA therapy, there is an urgent need to develop safe and effective LNP systems that can target extrahepatic organs. Here, we report on the development of sulfonium lipid nanoparticles (sLNPs) for systemic mRNA delivery to the lungs. sLNP effectively and specifically delivered mRNA to the lungs following intravenous administration in mice. No evidence of lung and systemic inflammation or toxicity in major organs was induced by sLNP. Our findings demonstrated that the newly developed lung-specific sLNP platform is both safe and efficacious. It holds great promise for advancing the development of new mRNA-based therapies for the treatment of lung-associated diseases and conditions.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
RNA Mensageiro
/
Nanopartículas
/
Lipídeos
/
Pulmão
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Nano Lett
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Estados Unidos